Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
August 10, 2023 07:00 ET | Source: Altimmune, Inc

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) Top-line...
August 03, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial...
August 01, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)

GAITHERSBURG, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b...
June 16, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023

GAITHERSBURG, Md., June 16, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
June 15, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

Presentation Selected for Best of EASL Summary Slides Altimmune to Host a NASH KOL and Investor Reception on June 22, 2023 GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc....
May 31, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
May 11, 2023 07:00 ET | Source: Altimmune, Inc

Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update

Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 ...
May 08, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
May 04, 2023 07:30 ET | Source: Altimmune, Inc

Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial...